NASDAQ:MGRX Mangoceuticals (MGRX) Stock Price, News & Analysis → Are you prepared for a Chinese 'invasion?' (From Behind the Markets) (Ad) Free MGRX Stock Alerts $0.30 -0.02 (-6.25%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$0.29▼$0.3450-Day Range$0.22▼$0.5252-Week Range$0.14▼$1.99Volume462,135 shsAverage Volume3.35 million shsMarket Capitalization$7.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Mangoceuticals alerts: Email Address Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> About Mangoceuticals Stock (NASDAQ:MGRX)Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.Read More MGRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGRX Stock News HeadlinesJune 15 at 1:58 AM | americanbankingnews.comHead to Head Survey: Mangoceuticals (NASDAQ:MGRX) vs. Global Cord Blood (NYSE:CORBF)June 6, 2024 | globenewswire.comMangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care TechnologyJune 4, 2024 | globenewswire.comMangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont TechnologiesMay 28, 2024 | globenewswire.comMangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American MarketsMay 23, 2024 | globenewswire.comMangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing EffortsMay 23, 2024 | investorplace.comMove Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.May 21, 2024 | investorplace.comWhy Is Mangoceuticals (MGRX) Stock Up 130% Today?May 21, 2024 | finanznachrichten.deMangoceuticals, Inc.: MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 MedicationsMay 21, 2024 | msn.comMangoceuticals Develops Oral GLP-1s: Stock SoarsMay 21, 2024 | globenewswire.comMangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 MedicationsMay 17, 2024 | finanznachrichten.deMangoceuticals, Inc.: MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market PenetrationMay 16, 2024 | investorplace.comMGRX Stock Earnings: Mangoceuticals Reported Results for Q1 2024May 16, 2024 | globenewswire.comMangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market PenetrationMay 2, 2024 | finance.yahoo.comMangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity RequirementMay 2, 2024 | globenewswire.comMangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq's Minimum Stockholders' Equity RequirementApril 25, 2024 | finance.yahoo.comMangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive CareApril 13, 2024 | investing.comMangoceuticals partners with Emifarma for ED product developmentApril 12, 2024 | globenewswire.comMangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) ProductsApril 10, 2024 | finance.yahoo.comThis Mangoceuticals Insider Increased Their Holding In The Last YearMarch 12, 2024 | finance.yahoo.comMangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) TreatmentMarch 12, 2024 | globenewswire.comMangoRx Officially Launches ‘PRIME' by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) TreatmentFebruary 27, 2024 | benzinga.comMangoceuticals Stock (NASDAQ:MGRX), Quotes and News SummaryFebruary 20, 2024 | finance.yahoo.comMangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue GrowthFebruary 20, 2024 | globenewswire.comMangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue GrowthFebruary 13, 2024 | finance.yahoo.comMangoceuticals, Inc. (MGRX)See More Headlines Receive MGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mangoceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today6/17/2024Next Earnings (Estimated)7/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:MGRX CUSIPN/A CIK1938046 Webwww.mangorx.com Phone833-626-4679FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,210,000.00 Net Margins-1,068.72% Pretax Margin-1,068.60% Return on Equity-864.10% Return on Assets-577.68% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.06 Sales & Book Value Annual Sales$730,000.00 Price / Sales10.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book7.50Miscellaneous Outstanding Shares24,820,000Free Float15,065,000Market Cap$7.44 million OptionableNot Optionable Beta2.10 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Eugene M. Johnston (Age 60)Chief Financial Officer Comp: $14kMs. Amanda Elizabeth Hammer (Age 38)Chief Operating Officer Comp: $105.42kKey CompetitorsOntrakNASDAQ:OTRKMarpaiNASDAQ:MRAIBioRestorative TherapiesNASDAQ:BRTXGreenbrook TMSNASDAQ:GBNHFFresenius Medical CareNYSE:FMSView All Competitors MGRX Stock Analysis - Frequently Asked Questions How have MGRX shares performed in 2024? Mangoceuticals' stock was trading at $0.2769 on January 1st, 2024. Since then, MGRX stock has increased by 8.3% and is now trading at $0.2999. View the best growth stocks for 2024 here. Are investors shorting Mangoceuticals? Mangoceuticals saw a increase in short interest in May. As of May 31st, there was short interest totaling 123,000 shares, an increase of 353.9% from the May 15th total of 27,100 shares. Based on an average daily trading volume, of 5,250,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.9% of the shares of the stock are sold short. View Mangoceuticals' Short Interest. When is Mangoceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 1st 2024. View our MGRX earnings forecast. How were Mangoceuticals' earnings last quarter? Mangoceuticals, Inc. (NASDAQ:MGRX) issued its earnings results on Monday, April, 1st. The company reported ($0.13) earnings per share (EPS) for the quarter. The business earned $0.24 million during the quarter. Mangoceuticals had a negative trailing twelve-month return on equity of 864.10% and a negative net margin of 1,068.72%. When did Mangoceuticals IPO? Mangoceuticals (MGRX) raised $5 million in an initial public offering on Tuesday, March 21st 2023. The company issued 1,300,000 shares at $4.00 per share. Boustead Securities acted as the underwriter for the IPO. How do I buy shares of Mangoceuticals? Shares of MGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MGRX) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mangoceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mangoceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.